CAN2109 / Canwell Biotech - LARVOL DELTA

A phse 1 study of CAN2109, a novel,long-acting, tumor-retained, immunoegenic cell death inducer (AACR 2026) - "Abstract is embargoed at this time."

Oncology

CAN2109: preclinical development of a novel long-acting immunogenic cell death (ICD) inducer for cancer therapy (SITC 2024) - P1 | "CAN2109 also has favorable ADME/PK/Tox properties and a safety profile when administered subcutaneously in mice, rats, and dogs. Conclusions Based on the superior efficacy and safety of CAN2019 in preclinical studies, the first-in-human Phase I dose-escalation trial for patients with advanced cancer was initiated in multi-clinical centers (NCT06332430)."

Immunogenic cell death • Preclinical • Oncology

Intratumoral CAN2109 in Subjects With Solid Tumors (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Canwell Biotech Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

Intratumoral CAN2109 in Subjects With Solid Tumors or Lymphomas (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Canwell Biotech Limited

Metastases • New P1 trial • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor